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To determine whether an association exists between 
group B streptococcus carriage and HIV infection, we 
recruited 1,857 pregnant women (21.7% HIV positive) 
from Queen Elizabeth Central Hospital, Blantyre, Malawi. 
Overall, group B streptococcus carriage was 21.2% and did 
not differ by HIV status. However, carriage was increased 
among HIV-positive women with higher CD4 counts.
Group B streptococcus (GBS) is the major cause of neonatal meningitis and septicemia in Malawi, a 
problem that has only recently been recognized (1). A 
similar pattern of disease has emerged from other countries 
in eastern and southern Africa (2–8). The geographic 
distribution of these reports led us to speculate that an 
association exists between GBS and HIV infection. 
Carriage of GBS is a prerequisite for the development of 
early-onset neonatal GBS disease (9) and is a convenient 
endpoint for a cross-sectional study to assess the interaction 
of GBS and HIV.
The Study
Pregnant women (≥16 years of age) in their third 
trimester of pregnancy were recruited from the labor ward 
of Queen Elizabeth Central Hospital, Blantyre (QECH), 
during October 2008–March 2010. Recruitment was 
performed by a single study midwife on Sunday–Thursday 
each week from 7:30 AM to 4:00 PM, when the midwife 
was not required to provide emergency care. Women were 
excluded if they were deemed to be too sick by the study 
midwife. Following the patient’s signed informed consent, 
medical and reproductive history was recorded, low 
vaginal and rectal swab specimens were obtained, and after 
appropriate counseling, a blood sample was obtained to 
either confi rm or determine HIV status. CD4 counts were 
determined for those who were HIV positive. In accordance 
with Ministry of Health Guidelines, prevention of mother-
to-child transmission care (PMTCT) was offered to women 
who were HIV infected (10); PMTCT was adapted as 
appropriate to the woman’s CD4 count. The mothers were 
not followed after they left the hospital.
Swab specimens were placed into Todd-Hewitt 
broth (Oxoid Ltd, Basingstoke, UK) supplemented with 
15 μg/mL nalidixic acid and 10 μg/mL colistin and then 
incubated for 18–24 h. GBS were identifi ed by phenotypic 
characteristics, CAMP test, and serologic analysis (Oxoid). 
Serotyping of GBS was performed by use of a commercial 
serotyping kit (Statens Serum Institut, Copenhagen, 
Denmark). HIV testing was conducted by using a method 
based on rapid tests (11).
The study aimed to recruit 1,950 women to show a 
GBS carriage prevalence increased by ≥40% in the HIV-
positive women at a signifi cance level of 5% and power 
of 80%. This assumed 20% HIV prevalence in the labor 
ward attendees (thus a 4:1 ratio of HIV-negative to HIV-
positive women) and 15% GBS carriage in HIV-negative 
women. Two analyses were planned a priori. The primary 
analysis was to compare GBS carriage prevalence by HIV 
status; the secondary analysis was the association of GBS 
carriage by CD4 count in HIV-infected women. The study 
was approved by the College of Medicine Research and 
Ethics Committee of the University of Malawi and the 
Ethics Committee of the London School of Hygiene and 
Tropical Medicine.
A total of 16,456 women attended QECH labor ward 
during the study period. Of these women, 11,861 attended 
on a recruitment day, and 8,099 attended during recruitment 
hours, of whom 1,857 (23%) were recruited into the study 
(Table 1). The 2 primary reasons for not enrolling women 
were that they were in the second stage of labor and that 
their hospitalization was caused by an emergency or due 
to a complicated pregnancy (50.8% of all attendees). The 
remaining nonrecruits were women who could not be 
assessed by the study midwife within the specifi ed time. 
During the same period, 14,783 total deliveries took 
place at QECH, with 380 multiple births (2.6%), 2,962 
caesarean sections (20.0%), 514 stillbirths (3.5%), 29 
neonatal deaths, and 20 maternal deaths recorded on the 
labor ward. The percentage of women in the study who 
had multiple births (2.7%) and caesarean sections (20.6%) 
was the same as that in the larger group attending the labor 
ward. However, the percentage with stillbirths (1.6%) was 
less, which is consistent with the exclusion of women who 
were attending the ward for complicated pregnancies or 
emergency medical conditions.
DISPATCHES
1932 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 10, October 2011
1Deceased.
Author affi liations: College of Medicine, Blantyre, Malawi (K.J. Gray, 
G. Kafulafula, M. Kamdolozi, G. Membe); Karonga Prevention 
Study, Karonga, Malawi (M. Matemba, N. French); and London 
School of Hygiene and Tropical Medicine, London, UK (N. French) 
DOI: http://dx.doi.org/10.3201/eid1710.102008
Group B Streptococcus Carriage and HIV
Of the study participants with HIV, >80% had been 
tested before attending QECH labor ward, most as a part 
of the PMTCT process. Only 125 (31%) of those with 
positive test results had received any formal HIV clinic 
care. GBS carriage was detected in 21.7% of the HIV-
negative women and 19.4% of the HIV-positive women (χ2 
= 0.99, p = 0.32) (Table 2). In the HIV-positive women, 
a difference in GBS carriage was noted by CD4 level: 
women with CD4 counts >500 cells/mm3 were >2× more 
likely than those with counts <200 cells/mm3 to be GBS 
carriers. When adjusted for antiretroviral treatment, the 
number of children previously borne, and age, this fi nding 
persisted (Table 2). Carriage in the HIV-infected group 
with CD4 counts >500 cells/mm3 (28.2%) was higher than 
in the HIV-uninfected women (21.7%), but the difference 
did not reach signifi cance in an unadjusted comparison (χ2 
= 2.65, df = 1, p = 0.11).
To test for unrecorded cotrimoxazole use as an 
explanation of the CD4-associated carriage fi ndings (i.e., 
that sicker women with more advanced disease might be 
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Table 1. Comparison of variables, including age, CD4 counts, and reproductive and medical history, for HIV-negative and HIV-positive
study participants, Malawi, 2008–2010* 
Variable
All study 
participants,
N = 1,857† 
HIV-positive
participants,
n = 402/21.7% 
HIV-negative
participants,
n = 1,454/78.3% p value 
Mean age, y (SD) 25.2 (5.9) 26.7 (5.5) 24.8 (5.9) <0.001 
No. (%) recruited during wet season (Nov–Mar) 1,057 (57.0) 234 (58.2) 820 (56.4) 0.57
Reproductive and medical history 
 Pregnancies, median no. (range) 1 (0–10) 2 (0–8) 1 (0–10) <0.001 
 Live births, median no. (range)  1 (0–10) 1 (0–7) 1 (0–10) <0.001 
 Previous neonatal death, no. (%) 45 (2.4) 11 (2.7) 34 (2.3) 0.65
 Median time since LMP, days (range)  275 (98–371) 275 (145–371) 276 (98–370) 0.17
 Unwell at labor ward attendance, no. (%) 114 (6.1) 33 (8.2) 81 (5.6) 0.05
 Membranes ruptured >18 h before enrolled, no. (%) 52 (2.8) 12 (3.0) 40 (2.8) 0.79
 Previous HIV test, no. (%) 1,664 (89.7) 368 (91.5) 1,296 (89.1) 0.16
 Taking ART, no. (%) – 83 (20.7) –
 Median duration of ART, mo (range) 4 (1–144) 
 Genital ulcer disease, no. (%) 46 (2.5) 32 (8.0) 14 (1.0) <0.001 
 Sexually transmitted disease, no. (%) 34 (1.8) 23 (5.7) 11 (0.8) <0.001 
 S-P use during last 4 wk of pregnancy, no. (%) 1,779 (96.0) 379 (94.3) 1,395 (96.9) 0.38
Examination and other findings 
 First stage of labor, no. (%) 1,298 (69.9) 279 (69.4) 1,019 (70.1) 0.79
 Premature labor before 36 wk, no. (%) 270 (14.5) 71 (17.7) 199 (13.7) 0.04
 Registered for PMTCT on labor ward, no. (%) – 333 (82.8)‡ –
 Mean birth weight (SD), kg 2.90 (0.54) 2.81 (0.58) 2.91 (0.52) <0.001 
 Delivery by cesarean section, no. (%) 383 (20.6) 76 (18.9) 307 (21.1) 0.33
 Stillbirth, no. (%) 30 (1.6) 13 (3.2) 17 (1.2) 0.004
 Multiple birth, no. (%) 50 (2.7) 10 (2.5) 40 (2.8) 0.77
Laboratory tests 
 Plasma sample for CD4 count, no. – 383§ –
 CD4 count, median (range) 370 (20–1595) 
 No. failed samples¶ 18 5 13
 GBS isolated, no. (%)# 390 (21.2) 77 (19.4) 313 (21.5) 0.4
  Serotype 
   1a 71 (18.2) 11 (14.3) 60 (19.2) 
   1b 24 (6.2) 1 (1.3) 23 (7.4) 
   2 40 (10.3) 9 (11.7) 31 (9.9) 
   3 152 (39.0) 32 (41.6) 120 (38.3) 
   4 1 (0.3) 0 1 (0.3) 
   5 93 (23.9) 23 (29.9) 70 (22.4) 
   6 (1 sample), 8 (2 samples) 3 (0.8) 0 3 (1.0) 
  Untypeable, no (%) 6 (1.5) 1 (1.3) 5 (1.6) 
*LMP, last menstrual period; ART, antiretroviral treatment; –, not applicable; S-P, sulfadoxine-pyrimethamine; PMTCT, prevention of mother-to-child 
transmission care; GBS, group B streptococcus. 
†Form for 1 participant was missing. 
‡No. includes only participants confirmed as HIV-positive. 
§15 failures, 4 samples not obtained. 
¶Contamination of the selective broth in 9 cases and incubator failure in 9 cases. 
#Failed samples excluded from denominator to derive percentage. 
more likely to take cotrimoxazole), we performed a post-
hoc subgroup analysis on women who had reported no 
previous HIV testing or care before their recent PMTCT 
test, considering it unlikely that they would be taking 
cotrimoxazole. In this group of 277 women (13 with 
missing CD4 counts), the trend for increasing odds of 
carriage with higher CD4 count persisted. The prevalence 
of carriage in the CD4 groups of <200, 200–500, and >500 
cells/mm3 was 15.9%, 19.1% (odds ratio [OR] 1.25, 200–
500 cells/mm3 vs. <200 cells/mm3), and 31.0% (OR 2.37, 
>500 cells/mm3 vs. <200 cells/mm3), respectively (p = 
0.03, by χ2 test for linear trend). This pattern was similar in 
the 125 participants who reported accessing HIV care, with 
ORs of 1.6 and 2.8 in the same CD4 group comparisons.
Conclusions
In the primary analysis comparing carriage prevalence 
by HIV status, no overall difference in GBS carriage by 
HIV status was detected. The overall carriage frequency 
of GBS of ≈20% is comparable with those in other reports 
from Africa and the industrialized world. However, in the 
subgroup analysis of HIV-positive women, contrary to our 
expectations, GBS carriage was signifi cantly increased at 
higher CD4 counts. Unrecorded use of antimicrobial drugs, 
particularly cotrimoxazole prophylaxis, as a confounder 
for this association was considered and dismissed as an 
explanation for these fi ndings.
Antiretroviral treatment was not shown as an 
independent risk factor for carriage, but the cross-sectional 
design of this study precludes any fi rm conclusions. 
With increasing numbers of HIV-positive women using 
antiretroviral drugs, the effect of treatment-induced 
improvements in CD4 count and the potential for increased 
GBS carriage merit further investigation.
Our results showed a trend toward higher GBS carriage 
in HIV-infected women with CD4 counts >500 cells/mm3 
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Table 2. Associations with GBS carriage among 340 pregnant women with and without HIV infection, Malawi, 2008–2010* 
Variable
GBS carriage, no. positive for 
variable/no. total (%)  OR (95% CI) Adjusted OR (95% CI) 
All study participants 390/1,857 (21.0) – –
HIV-negative participants 313/1,441 (21.7) Reference Reference 
HIV-positive participants 77/397 (19.4) 0.88 (0.66–1.17) 0.84 (0.63–1.12) 
Age group, y† 
 16–19 68/345 (19.7) 2.29 (0.68–7.76) 1.41 (0.40–4.92) 
 20–24 122/582 (21.0) 2.48 (0.74–8.28) 1.96 (0.58–6.63) 
 25–29 113/498 (22.7) 2.74 (0.82–9.18) 2.43 (0.72–8.18) 
 30–34 60/261 (23.0) 2.79 (0.82–9.48) 2.59 (0.76–8.88) 
 35–39 24/122 (19.7) 2.29 (0.64–8.15) 2.03 (0.56–7.33) 
 >40 3/31 (9.7) Reference Reference 
First pregnancy  137 (24.0) 1.30 (1.01–1.65) 1.62 (1.19–2.19) 
Second or subsequent pregnancy 244 (19.6) Reference Reference 
Recruited during rainy season 235 (22.4) 1.18 (0.94–1.50) –
Recruited during nonrainy season 155 (19.6) Reference –
Birth weight <2.5 kg 
 No 307 (21.5) Reference –
 Yes 71 (19.4) 0.88 (0.65–1.17) –
Multiple birth 
 No 381 (21.3) Reference –
 Yes 9 (18.0) 0.81 (0.34–1.71) –
HIV-positive subgroup‡ 
 Antiretroviral treatment 
  No 67 (20.4) Reference Reference 
  Yes 15 (18.1) 0.91 (0.45–1.75) 1.14 (0.58–2.26)§ 
 CD4 cell count/mm3¶
  <200 9 (14.1) Reference Reference 
  200–499 34 (17.2) 1.27 (0.57–2.81) 1.30 (0.58–2.92)§ 
  >500 33 (28.2) 2.40 (1.07–5.41) 2.55 (1.10–5.90) 
*GBS, group B streptococcus; OR, odds ratio; CI, confidence interval; –, not applicable. Adjusted OR derived from logistic regression by use of backward 
stepwise approach. Final model retained variables with p value <0.1 along with age group and parity because of their known association with GBS 
carriage. 
†Ȥ2 test for linear trend, p = 0.93. 
‡Ȥ2 test for linear trend, p = 0.01. 
§Adjusted model includes age group, first pregnancy vs. second or subsequent pregnancies; antiretroviral treatment, and CD4 count for the HIV-positive 
subgroup. 
¶19 participants had no CD4 count available. 
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than in the HIV-uninfected women. This association 
may be consistent with a GBS-specifi c immune defect, 
which would concur with what we understand about HIV 
immunopathology and related capsulate bacteria (12). We 
propose that this higher carriage is obscured at lower CD4 
counts by competitive exclusion of GBS in the vagina of 
women with advanced HIV as a consequence of ecologic 
changes in the microbial fl ora (13). Increased presence of 
bacterial vaginosis and anaerobes at low CD4 counts is a 
feature of HIV, and these conditions may alter the ability 
of GBS to colonize the vagina (14,15). Specifi c studies to 
investigate anti-GBS immunity and the interactions of the 
microbial fl ora in HIV-infected women are required.
Neonatal GBS disease is common in Africa, and 
disease risk is intimately connected to GBS carriage. The 
public health consequences of these carriage fi ndings 
are unclear at present, but further investigation of the 
interaction of HIV and GBS carriage and risk of neonatal 
disease is merited, given the recent rise in frequency of 
GBS infection. 
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